Pediatric Radiology

, Volume 36, Issue 10, pp 1048–1056 | Cite as

Age-related findings on MRI in neurofibromatosis type 1

  • Deepak S. Gill
  • Shelley L. Hyman
  • Adam Steinberg
  • Kathryn N. North
Original Article

Abstract

Background

T2 hyperintensities (T2H) on MRI are the most common CNS lesions in individuals with neurofibromatosis type 1 (NF1).

Objectives

The aim was to determine the frequency, signal characteristics and localization of T2H at different ages. In addition, we examined the sensitivity of different MR imaging sequences in detecting these lesions.

Materials and methods

We studied prospectively a cohort of children, adolescents and young adults with NF1 using T2-volume (T2-V) and conventional MRI sequences. Lesions were designated as either discrete or diffuse, and the region of signal abnormality was recorded. A total of 103 patients were studied (age range 8.0–25.4 years, mean 13.9 years).

Results

The frequency, size, and intensity of T2H decreased with age in the basal ganglia (BG) and the cerebellum/brainstem (CB/BS). The majority of thalamic and CB/BS lesions were diffuse. Of the total cohort, 80% had diffuse bilateral hippocampal hyperintensities and 18.4% had hemispheric lesions best demonstrated on FLAIR; there was no significant difference in the frequency or signal intensity of hemispheric lesions with age.

Conclusion

Lesions in the cerebral hemispheres and hippocampus imaged by MR do not change in prevalence over time, suggesting a different pathological basis from the lesions in the in BG and CB/BS that resolve with age. FLAIR and T2-V sequences are more sensitive in detecting lesions than standard T2-weighted sequences.

Keywords

Neurofibromatosis type 1 MRI Hippocampus 

Introduction

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder with an estimated prevalence of 1 in 3,500 [1]. The NF1 gene [2, 3, 4] is a tumour suppressor gene and encodes the protein neurofibromin, which is expressed in neurons and glial tissue in the central and peripheral nervous system [5, 6, 7]. NF1 is characterized by aberrant cell growth and differentiation of neuronal and pigmentary cell lines resulting in neurofibromas, café au lait spots, and Lisch nodules. Alterations in the growth and maturation of CNS tissue results in CNS tumours such as optic pathway gliomas [6], macrocephaly associated with an increase in the ratio of grey matter to white matter [8], and increased surface area of the corpus callosum [9].

The most common CNS lesions in NF1 are seen by MRI on T2-weighted (T2-W) images as areas of hyperintensity (prolongation of T2). These lesions are usually isointense on T1-weighted (T1-W) images, they exert no mass effect, there is no surrounding oedema, and they do not enhance following administration of contrast material [10]. The T2 hyperintensities (T2H) are reported to occur in 60–70% of children with NF1 [11] (although figures vary from study to study depending on the age range of the patients and the imaging techniques used). They are also referred to as hamartomas [12] or ‘UBOs’ (unidentified bright objects) [13] and are most commonly seen in the globus pallidus, brainstem and thalamus [14]. The pathology underlying these lesions is unclear. Early autopsy studies of brains from adults with NF1 found evidence of focal heterotopia, disordered cortical architecture with random orientation of neurons and focal proliferation of glial cells [15, 16]. These observations laid the basis for the assumption that the neuropathology of NF1 is characterized by dysplasia or hamartomatous changes. Neither of these studies correlated the histological findings with neuroimaging and there is only one study that has done so [1]. In this study it was concluded that the high signal intensity lesions on MRI may represent increased fluid within the myelin associated with hyperplastic or dysplastic glial proliferation.

Cross-sectional data suggest that the number of T2H decrease with age and that the lesions become rare in the third decade [10, 12, 17]. Hyman et al. [18] studied 32 patients with NF1 prospectively over an 8-year period and demonstrated a significant decrease in size, number and intensity of T2H.

It is not known whether the same neuropathology underlies all T2H. There is variability in the site of the T2H as well as variation in their signal intensity ranging from discrete hyperintensities to more diffuse lesions [14]. Some lesions have T1-related changes [14, 19, 20, 21] and there is occasionally contrast enhancement with gadolinium [14]. Only limited conclusions can be drawn from published studies due to the small number of patients studied [14], retrospective study design [10, 17, 22] and the inclusion of patients with other CNS and ocular pathology that may have biased the studies with an increased likelihood of coexistent T2H [22]. Individual studies have used different imaging sequences and have not taken into account the ability of more sensitive MRI sequences to detect signal abnormalities. In addition, in no study have the parameters been defined for defining what constitutes an MRI T2H, i.e. whether diffuse areas of T2H are the same as discrete and well-circumscribed lesions.

We have performed neuroimaging of a large cohort of children, adolescents and young adults with NF1, ascertained prospectively in our clinic. We have performed a cross-sectional analysis of MRI findings to determine the frequency, signal characteristics and localization of T2H at different ages. In addition we examined the relative sensitivity of different MR imaging modalities in detecting these lesions including conventional T2-W imaging, FLAIR and T2-volume (T2-V) sequences.

Materials and methods

Subjects

The patients were ascertained from the neurofibromatosis clinic at the Children’s Hospital at Westmead in Sydney, Australia. All members of the cohort were recruited as part of a study of both cognition and MRI features of NF1. All individuals were examined by a neurologist and satisfied the diagnostic criteria for NF1. Patients were excluded if there was a history of CNS tumour, or epilepsy. None of the patients had significant visual or hearing impairment. A total of 103 patients were recruited. This study was approved by the Ethics Committees of the Children’s Hospital at Westmead and the United States Army Research and Materiel Command. Some of the data from 27 patients have been published previously as part of our study of the natural history of cognitive deficits in NF1 [18].

Procedure

The MRI examinations were performed on a magnet operating at 1.5 T (ACS-NT; Philips, The Netherlands). MRI sequences were sagittal T1, axial T2, axial FLAIR, T2V, coronal FLAIR and axial T1-W imaging following intravenous administration of gadopentetate dimeglumine at 0.1 mmol/kg (Magnevist, Berlex Laboratories, Wayne, N.J.). Typical imaging parameters were TR/TE 500/15 ms for axial T1-W images before and after contrast enhancement, TR/TE 3,600/120 ms for axial T2-W sequences, and TR/TE/TI 7,000/130/2,200 ms for axial FLAIR. T2-V parameters were TR/TE 7,000/110 ms. The images were obtained with 5-mm thick sections with a 1-mm spacing, 220-cm field of view, and a 512×256 matrix, except for T2-V where 100 sections were obtained each 1.60 mm in thickness, giving an almost contiguous appearance.

The MRI examinations were reported independently by the radiologist on duty at the time of performance of the MRI. The scans were then reported by a radiologist (A.S.) and a neurologist (D.G.) together. Two neurologists (D.G. and K.N.) reported the scans together, 1 year after the initial analysis. The 1-year interval reduced the likelihood of bias of previous interpretation by the principal investigator, D.G. At the time of the second report D.G. was blinded to the result of the first reporting session. D.G. observed that the variability between the two reporting sessions, although not formally calculated, was low; however a further consensus meeting was convened with D.G., K.N. and A.S. so agreement was reached on lesion presence or absence and signal characteristics. K.N. and A.S. were blinded to the results of other reports except at the consensus meeting. D.G. and A.S. were blinded to the clinical history other than NF1. K.N. had prior knowledge of the clinical history but not of the results of detailed cognitive testing.

Each area of abnormal signal intensity (T2H) on T2-W images was assigned as being either discrete or diffuse. Discrete lesions were those that were well circumscribed, having a margin that was distinct from normal tissue. Diffuse lesions were lesions that were not discrete; the margins of these lesions were poorly defined. Examples of these lesions are shown in Fig. 1. There was complete agreement between all reporters for discrete lesions. There was occasional disagreement for diffuse lesions, and this was resolved at the consensus meeting. The region of the signal abnormality was recorded. The different regions were basal ganglia (BG), thalamus, corpus callosum, and the cerebellum and brainstem (grouped together, CB/BS). Lesions that were outside either these regions or the diencephalon were termed ‘hemispheric’. Specific note of the signal change both on T2 and FLAIR was made within the hippocampus and mesial temporal structures as it became apparent during the study that a number of individuals had bilateral diffuse signal change in this region. The appearance of each individual lesion was reviewed in the different sequences (standard T2-W, FLAIR, T2-V sequence) and note made of any differences in the sensitivity of each sequence to detect the lesions.
Fig. 1

MRI. a Discrete right BG, diffuse left BG and diffuse bilateral thalamic T2H in an 8-year-old patient. b ‘Halo’ effect with increased signal on T1-W imaging at the edge of a right globus pallidus lesion

This study includes MRI data on 103 patients (49 males and 54 females) with an age range of 8.0 to 25.4 years, mean 13.9 years. For the purpose of cross-sectional analysis the cohort was divided into five groups of roughly equal size: group 1 8–9 years (n=18), group 2 10–11 years (n=21), group 3 12–13 years (n=27), group 4 14–19 years (n=22), group 5 20–25 years (n=15).

Interpretation of T2-W images has been the basis of the majority of MRI studies in NF1, and it was this sequence that was studied in detail to assess the frequency, size and intensity of lesions (T2H). Each region in each individual was noted for the presence or absence of T2H either discrete or diffuse, and a percentage occurrence of T2H was calculated for each age cohort. The percentage of individuals with discrete T2H only, diffuse T2H only and both discrete and diffuse T2H in the BG was calculated for each cohort. The total number of lesions (discrete or diffuse) on standard T2-W sequences was recorded.

Results

Of the total cohort, 66% had T2H in BG, CB/BS, thalamus or CC. The proportion of children with T2H was highest in groups 1 (84%), 2 (81%) and 3 (78%). T2H were present in 55% of patients in group 4 and in only 20% of individuals in the oldest group 5. The frequency, size and intensity of T2H in the BG and CB/BS decreased with age (Figs. 2 and 3) For example, of the 13 children (68%) with BG T2Hs in group 1, all had at least one discrete T2H, in addition two of the children had diffuse areas of T2H (Fig. 3) . Only one individual over the age of 20 years (group 5), had a T2H in the BG, and this lesion was diffuse. The incidence of CB/BS lesions showed a similar decline with age; 85% of group 1 had T2H compared to 13% of group 5. T2H in the corpus callosum were seen in 20% of individuals in groups 1–4, but were absent in all 15 individuals in group 5. There was a small increase in the frequency of T2H in the thalamus between the two younger age groups, but thereafter the number of T2H declined and no individuals in group 5 had T2H in the thalamus.
Fig. 2

The percentage of patients in each age group with T2H (discrete or diffuse) in different brain regions

Fig. 3

Occurrence and intensity of BG T2H in relation to age

The majority of the BG T2H (68%) were discrete. Lesions in the thalamus (46/50, 92%) and the CB/BS (25/52, 67.5%) were mostly diffuse (Fig. 4). T2-V was the most sensitive sequence in demonstrating T2H. This sequence showed change in all patients with T2H changes. Even minor signal change on conventional T2-W studies resulted in definite signal on T2-V sequences. In addition, the T2-V sequence demonstrated a more extensive lesion or multiple lesions in a number of patients in whom conventional T2-W imaging demonstrated just a single lesion (Fig. 5). All lesions seen on FLAIR were also seen on T2-V sequences. Of the 14 discrete lesions in the BG, FLAIR was equally sensitive to T2-W sequences in detecting the lesions, although the lesions were more easily seen in 7/14 with the FLAIR sequence.
Fig. 4

The number and intensity of T2H in different brain regions (BG basal ganglia, CB/BS cerebellum/brainstem, Thal thalamus, CC corpus callosum)

Fig. 5

Increased complexity of right BG lesion when seen on T2-V (a) compared to T2-W image (b) in an 8-year-old child

Diffuse bilateral hippocampal T2H (DBHH) were present in 80% of the cohort (Fig. 6). These lesions were consistently more easily seen on FLAIR. Subtle diffuse T2-W changes were seen; however, these are also seen in normal individuals and for the purpose of this study the term DBHH was only assigned to an individual who had signal change on both T2 and FLAIR. In three patients the signal extended into the parahippocampal gyrus and in two patients the signal change also involved the amygdala (Fig. 7). The incidence of DBHH was highest in groups 1–4 (90%, 82%, 85%, 82% respectively); in contrast 60% of group 5 had DBHH. Seven patients had bulky hypothalamic lesions, but only two of these patients had signal change, better demonstrated by FLAIR.
Fig. 6

Diffuse bilateral hippocampal hyperintensities seen on T2-W image (a) in 13-year-old girl, better demonstrated with FLAIR (b)

Fig. 7

Amygdala hyperintensity demonstrated by FLAIR in a 13-year-old patient

The hemispheric, non-diencephalic lesions were the most diverse in appearance and location. Of the 103 patients, 19 (18.4%) had 20 hemispheric lesions that were identified on either T2 or FLAIR. Ten of the lesions were cortical; five were in the subcortical white matter and four in the deep white matter. FLAIR was superior to conventional T2-W imaging in demonstrating the hemispheric lesions in 13 of the 19 patients (Fig. 8). Of ten cortical lesions, eight had mass effect and all were better visualized with FLAIR. In two patients the lesions were seen only on FLAIR. Eleven patients had lesions in the frontal lobes, of which the majority were located in either the cingulate gyrus or the gyrus rectus. A single hemispheric lesion enhanced with gadolinium (Fig. 9); the others showed no contrast enhancement. Two patients had insular cortical changes that appeared to be extensions of the signal change seen in the hippocampus.
Fig. 8

Superior sensitivity of FLAIR in detecting cortical lesions compared to T2-W sequence. FLAIR (a) and T2-W (b) images in a 10-year-old child with a lesion in the right frontal lobe. c FLAIR image in a 12-year-old child demonstrating a lesion of the superior frontal gyrus. d FLAIR image in a 10-year-old child demonstrating a left gyrus rectus lesion

Fig. 9

Contrast-enhanced T1-W image demonstrating a lesion in the cingulate gyrus in a 13-year-old patient

There were no significant differences in the frequency of hemispheric lesions among groups 1–5. Six patients with hemispheric T2H had previous neuroimaging (intervals of 7–8 years). In four of the six patients, the lesions were not present on the first scan. However FLAIR was not performed on the initial scans, and this appeared to be the most sensitive sequence for detecting the lesions. Seven patients (ages 8, 9, 10, 12, 13, 13, and 21 years of age, respectively) with cortical or subcortical lesions had further follow-up MRI over 1–2 years during the period of this study, and no interval change was detected.

Of the 39 patients with discrete T2H in the BG, 27 had signal changes in the same location on T1-W imaging with increased signal in 25 of the 27; in two patients the T1 signal was low intensity. The increased T1 signal was circumferential in 13 patients giving the impression of a ring or haloing effect on T1 axial or sagittal views (Fig. 10). Of the 14 BG lesions that were strongly hyperintense on axial T2-W imaging, five displayed this ’halo“ effect; this effect was present in association with only one of the diffuse T2H lesions. Of the 12 patients in whom the T2-W images were not as intense, or in whom there was discordance between the observers as to the discrete nature of the lesion, none had T1-related changes, i.e. T1 haloing is a feature in only the most highly intense T2H lesions. One patient demonstrated a haloing effect on T2-V sequences.
Fig. 10

Axial T2-V image showing a left BG lesion with relative hyperintensity at the periphery of lesion compared to the central area in a 9-year-old girl

Discussion

We report the neuroimaging findings in the largest prospective MRI study of individuals with NF1 and demonstrate the diverse nature of T2H in both their anatomical location and intensity. BG T2H are more likely to be discrete whereas lesions in the thalamus, brainstem and cerebellum are rarely discrete and discerning the limits of individual lesions in these sites is difficult. The number and intensity of T2H diminish with age in the BG, cerebellum, brainstem and thalamus. Hemispheric and hippocampal lesions may appear over time; this suggests that they have a different pathogenetic basis from classic BG, cerebellar, brainstem and thalamic T2H. The signal characteristics on T2 imaging may be the only common feature shared by BG and the lesions of other sites in NF1.

A weakness of our study was that our patient population had a significant selection bias; the patients were cooperative and were able to undergo nonsedated procedures. Younger patients, patients with severe cognitive impairment, epilepsy, optic pathway tumours and other tumours were excluded from the analysis; T2H occur in almost all patients with NF1 and CNS tumours [7]. Our radiological findings thus represent the milder end of the clinical spectrum of NF1. We undertook a blinded method of reporting and a consensus view. In this study, however, interrater reliability of detection of signal change was not tested.

Of our cohort, 18.4% had lesions in the cerebral hemispheres that were predominantly cortical or subcortical. These lesions characteristically have high signal on T2-W imaging, and are most easily visualized on FLAIR. These lesions are heterogeneous and appear to be distinct from the lesions in the BG, brainstem, cerebellum and thalamus. The lesions did not change over a follow-up period of 12–24 months in seven patients. The hemispheric lesions were present in all age groups and did not decrease in prevalence with age. The absence of such findings in a previous study [18] may reflect differences in imaging techniques, as FLAIR appears to be more sensitive for detecting hemispheric lesions; however it is also possible that these lesions had developed over time. The pathological correlate of these lesions is unknown. We speculate that they represent glial heterotopia described in the early studies of Rosman and Pearce [15]. The presence of T2 signal abnormality, however, would be atypical for heterotopic lesions. The cortical lesions may represent areas of disordered proliferation or increased astrogliosis, such as has been observed in autopsy brain specimens from patients with NF1 [7]. Others have observed malformations of cortical development (MCD) in individuals with NF1 and severe mental retardation and epilepsy [23]; this may represent a rare and extreme end of the spectrum of cortical dysplasia in NF1. The diagnosis of epilepsy was an exclusion criterion in our study. So by definition the lesions in our study were not clinically epileptogenic; however the relationship between cognitive impairment and cortical lesions and NF1 needs to be evaluated.

We observed a high prevalence of signal change within the hippocampus with 80% of the cohort demonstrating DBHH. A previous study looking specifically at the use of FLAIR in NF1 has shown signal change within the hippocampus [24]. We observed that there was a spectrum of signal change in the hippocampi with some individuals having minimal diffuse signal change on T2-W images without changes on FLAIR. This led to some discordance amongst investigators, and hence we assigned DBHH to those individuals who had signal change on both T2-W and FLAIR sequences. One weakness of our study was that we did not have an age-matched control group for comparison, so we could not specifically comment on the relevance in our study population of the finding of minimal signal change in the hippocampal structures on T2-W images alone; however the reporting radiologist and the investigating radiologist deemed these appearances to be within normal limits. Some individuals demonstrated signal change on FLAIR not just restricted to the hippocampi but also of the parahippocampal structures, amygdala and extension into the insula. The involvement of limbic structures has not been previously highlighted in human studies in NF1. Interestingly, in the mouse model of NF1, defects in behaviour and learning are thought to be suggestive of disordered hippocampal function, either due to abnormal function due to unregulated ras (regulator protein) activity during hippocampus-dependent learning, or to abnormal neurofibromin-mediated signalling in both the adult and developing hippocampus [25].

The pathological correlate of T2H remains controversial. In vitro studies have shown the NF1 gene to be a tumour suppressor gene [26, 27]. The expression of the gene product, neurofibromin, is predominantly restricted to neuronal tissue in adults. Part of the protein encoded by neurofibromin shows high sequence homology with the GAP (GTPase activator protein) family of proteins that interact with ras proteins that regulate cell growth and differentiation, therefore acting as a negative regulator of neurotrophin-mediated signalling [28]. Immunohistochemical studies have demonstrated upregulation of glial fibrillary acidic protein (GFAP), leading to the suggestion that this reactive astrogliosis may be an important pathogenetic mechanism in NF1 [29]. On this basis it has been proposed [10] that T2H in the BG, brainstem, thalamus and cerebellum represent the formation of a chemically abnormal myelin sheath that is subsequently broken down to be replaced by myelin with a more stable form. The “haloing” effect on T1-W images may reflect the presence of more stable myelin being laid down at the centre of a T2H, best seen in the BG. The fact that this observation appears to be unique for the lesions within the BG implies that the stable formation of myelin in the BG may be different from that in other regions.

The diversity of the hemispheric (cortical and subcortical), and hippocampal MRI lesions and the relative lack of change in prevalence with age, suggests that lesions in these regions behave differently to those in the BG and CB/BS.

We observed that the BG have a propensity towards more intense and discrete T2H. Using fine sections and T2-V sequences, we also demonstrated that, with increased resolution, a single T2H can actually be comprised of a number of poorly delineated lesions, i.e. the lesion count is affected by the sensitivity of the imaging technique used. This implies that the absolute number of lesions may not be accurate in published studies whose aim was to correlate the number of T2H with cognitive deficits [30]. The imaging technique used may determine whether a lesion is discrete or diffuse and the discrete nature of a T2H may be related to the intrinsic anatomy of the structure containing the lesion (e.g. globus pallidus) rather than true anatomical or physiological differences. As imaging becomes even more sensitive, the frequency of T2H may approach 100% in the younger age group. If T2H indeed represent a developmental or dysplastic change in the CNS in NF1, then this is likely to be a feature of the disorder in the vast majority of patients. Thus it will be increasingly important to distinguish between lesions in different locations and with different signal characteristics (e.g. intensity, discrete or diffuse distribution) in research studies of the pathogenesis and clinical associations of these MRI lesions.

Conclusion

MRI lesions in individuals with NF1 in the cerebral hemispheres and hippocampus did not change in prevalence over time, suggesting a different pathological basis to lesions in the BG and CB/BS that resolve with age. FLAIR and T2-V were more sensitive in detecting CNS lesions than standard T2-W and the prevalence of T2H in children with NF1 is likely to approach 100% as imaging techniques become more sensitive.

Notes

Acknowledgements

This research was supported by the Department of Defense Neurofibromatosis Research Program, managed by the U.S. Army Medical Research and Materiel Command (USAMRMC; award number DAMD17-00-1-0534). We are grateful to Dr. Sridhar Gibikote for his helpful comments on the significance of the radiological findings and Mrs. Susanne Smith for her administrative support.

References

  1. 1.
    DiPaolo DP, Zimmerman RA, Rorke LB, et al (1995) Neurofibromatosis type 1: pathologic substrate of high-signal intensity foci in the brain. Radiology 195:721–724PubMedGoogle Scholar
  2. 2.
    Cawthon RM, Weiss M, Xu G, et al (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193–201PubMedCrossRefGoogle Scholar
  3. 3.
    Wallace MR, Marchuk DA, Andersen LB, et al (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181–186PubMedCrossRefGoogle Scholar
  4. 4.
    Xu G, O’Connell P, Viskochil D, et al (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599–608PubMedCrossRefGoogle Scholar
  5. 5.
    DeClue JE, Cohen BD, Lowy DR (1991) Identification and characterization of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 88:9914–9918PubMedCrossRefGoogle Scholar
  6. 6.
    Gutmann DH, Wood DL, Collins FS (1991) Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 88:9658–9662PubMedCrossRefGoogle Scholar
  7. 7.
    North K, Ratner N (2003) The brain in neurofibromatosis type 1. In: Fisch GS (ed) Genetics and genomics of neurobehavioural disorders in contemporary clinical neurosciences series. Humana Press, Totowa, pp 97–135Google Scholar
  8. 8.
    Moore BD III, Slopis JM, Jackson EF, et al (2000) Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 54:914–920PubMedGoogle Scholar
  9. 9.
    Kayl AE, Moore BD III, Slopis JM, et al (2000) Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention-deficit hyperactivity disorder. J Child Neurol 15:90–96PubMedGoogle Scholar
  10. 10.
    Sevick RJ, Barkovich AJ, Edwards MSB, et al (1992) Evolution of white matter lesions in neurofibromatosis type 1: MR findings. AJNR 159:171–175Google Scholar
  11. 11.
    North KN, Riccardi MD, Samango-Sprouse C, et al (1997) Cognitive function and academic performance in neurofibromatosis 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 48:1121–1127PubMedGoogle Scholar
  12. 12.
    Aoki S, Barkovich AJ, Nishimura K, et al (1989) Neurofibromatosis type 1 and 2: cranial MR findings. Radiology 172:527–534PubMedGoogle Scholar
  13. 13.
    DeBella K, Poskitt K, Szudek J, et al (2000) Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 54:1646–1650PubMedGoogle Scholar
  14. 14.
    Van Es S, North KN, McHugh K, et al (1996) MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 26:478–487PubMedCrossRefGoogle Scholar
  15. 15.
    Rosman NP, Pearce J (1967) The brain in multiple neurofibromatosis (von Recklinghausen’s disease): a suggested neuropathological basis for the associated mental defect. Brain 90:829–838PubMedCrossRefGoogle Scholar
  16. 16.
    Rubinstein LJ (1986) The malformative central nervous system lesions in the central and peripheral forms of neurofibromatosis: a neuropathological study of 22 cases. Ann N Y Acad Sci 486:14–29PubMedCrossRefGoogle Scholar
  17. 17.
    Itoh T, Magnaldi S, White RM, et al (1994) Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. AJNR 15:1513–1519PubMedGoogle Scholar
  18. 18.
    Hyman SL, Gill DS, Shores EA, et al (2003) Natural history of cognitive deficits and their relationships to MRI T2-hyperintensities in NF1. Neurology 60:1139–1145PubMedGoogle Scholar
  19. 19.
    Mirowitz SA, Sartor K, Gado M (1989) High-intensity basal ganglia lesion on T1 weighted MR images in neurofibromatosis type-1. AJNR 10:1159–1163PubMedGoogle Scholar
  20. 20.
    Steen RG, Taylor JS, Langston JW, et al (2001) Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. AJNR 22:810–817PubMedGoogle Scholar
  21. 21.
    Terada H, Barkovich AJ, Edwards MSB, et al (1996) Evolution of high-intensity basal ganglia lesions on T1-weighted MR in neurofibromatosis type 1. AJNR 17:755–760PubMedGoogle Scholar
  22. 22.
    Ferner RE, Chaudhuri R, Bingham J, et al (1993) MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 56:492–495PubMedCrossRefGoogle Scholar
  23. 23.
    Balestri P, Vivarelli R, Grosso S, et al (2003) Malformations of cortical development in neurofibromatosis type 1. Neurology 61:1799–1801PubMedGoogle Scholar
  24. 24.
    Yamanouchi H, Kato T, Matsuda H, et al (1995) MRI in neurofibromatosis type I: using fluid-attenuated inversion recovery pulse sequences. Pediatr Neurol 12:286–290PubMedCrossRefGoogle Scholar
  25. 25.
    Silva AJ, Frankland PW, Marowitz Z, et al (1997) A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 15:281–284PubMedCrossRefGoogle Scholar
  26. 26.
    Legius E, Marchuk DA, Collins FS, et al (1993) Somatic deletion of neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3:122–126PubMedCrossRefGoogle Scholar
  27. 27.
    Shannon KM, O’Connell P, Martin GA, et al (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597–601PubMedCrossRefGoogle Scholar
  28. 28.
    Bollag G, McCormick F (1991) Differential regulation of Ras GAP and neurofibromatosis gene product activities. Nature 351:576–579PubMedCrossRefGoogle Scholar
  29. 29.
    Nordlund ML, Rizvi TA, Brannan CI, et al (1995) Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J Neuropathol Exp Neurol 54:588–600PubMedGoogle Scholar
  30. 30.
    Hofman KJ, Harris EL, Bryan RN, et al (1994) Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 124:S1–S8PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Deepak S. Gill
    • 1
  • Shelley L. Hyman
    • 2
  • Adam Steinberg
    • 3
  • Kathryn N. North
    • 1
    • 2
  1. 1.The T. Y. Nelson Department of NeurologyThe Children’s Hospital at WestmeadSydneyAustralia
  2. 2.Neurogenetics Research UnitThe Children’s Hospital at WestmeadSydneyAustralia
  3. 3.Department of RadiologyThe Children’s Hospital at WestmeadSydneyAustralia

Personalised recommendations